Irbesartan/Hydroklortiazid Actavis

Irbesartan/Hydrochlorothiazide, the active ingredient in Irbesartan/Hydrochlorothiazide Actavis, is an angiotensin II receptor blocker combined with a thiazide diuretic presented as a tablet for oral use. It is prescribed to lower elevated blood pressure in adult patients with hypertension, often in those who require additional diuretic therapy.

GNH USA supplies Irbesartan/Hydrochlorothiazide Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is used to manage hypertension and related cardiovascular conditions. - Hypertension: lowers systolic and diastolic blood pressure in adults. - Hypertensive chronic kidney disease: helps control blood pressure and reduces proteinuria. - Hypertension in type 2 diabetes: improves blood pressure control and may protect renal function.

The combination may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances such as low potassium - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Significant electrolyte imbalance (e.g., hyponatremia) - Allergic reactions including rash or angioedema - Pancreatitis (rare)

Before prescribing Irbesartan/Hydrochlorothiazide, clinicians should consider several safety precautions. - Renal function: assess kidney function and monitor serum creatinine. - Electrolytes: check potassium and sodium levels regularly. - Volume depletion: avoid in patients with dehydration or on high‑dose diuretics. - Pregnancy: contraindicated in the second and third trimesters; avoid use. - Concomitant drugs: review for interactions with potassium‑sparing agents or NSAIDs. - Store at ambient temperature: keep below 25 °C, protect from moisture in the original packaging.

Irbesartan/Hydrochlorothiazide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - ACE inhibitors or other ARBs: additive renal effects and hyperkalemia. - NSAIDs: may blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - Lithium: increased lithium levels, monitor for toxicity. - Cyclosporine or tacrolimus: may increase serum creatinine. - Antidiabetic agents: diuretic‑induced glucose changes may require dose adjustment.